1. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007;15(14):4674-99.

2. Rosen IM, Sams RW 2nd. Common questions in managing hyperlipidemia. 2006;33(4):903-21.

3. Fowler SB, Kelly M, Ruh D, Johnson-Wells D. Management of lipid disorders for stroke prevention. J NeurosciNurs. 2006;38:282-7.

4. Castilla-Guerra L, Fernandez-Moreno Mdel C, Alvarez-Suero J. Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. Eur J Intern Med. 2009;20(6): 586-90.

5. Mangin EF, Robles GI, Jones WN, Ford MA, Thomson SP. Comparing hyperlipidemia control with daily versus twice-weekly simvastatin. Ann Pharmacother. 2004;38(11):1789-93.

6. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291(18): 2243-52.

7. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82(4B):3J-10J.

8. Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101(11):1606-13.

9. Mukhtar RY, Reckless JP. Statin-induced myositis: a commonly encountered or rare side effect. CurrOpinLipidol. 2005;16(6):640-7.

10. Araujo FB, Barbosa DS, Hsin CY, Maranhao RC, Abdalla DS. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis. 1995;117(1):61-71.

11. Yang RL, Shi YH, Hao G, Li W, Le GW. Increasing Oxidative Stress with Progressive Hyperlipidemia in Human: Relation between Malondialdehyde and Atherogenic Index. J ClinBiochemNutr. 2008;43(3):154-8.

12. Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, et al. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during ator- vastatin and fenofibrate therapy. Free RadicBiol Med. 2007;42(5):698-705.

13. Sefi M, Fetoui H, Makni M, Zeghal N. Mitigating effects of antioxidant properties of Artemisia campestris leaf extract on hyperlipidemia, advanced glycation end products and oxidative stress in alloxan-induced diabetic rats. Food ChemToxicol. 2010;48(7):1986-93.

14. Ponce-Canchihuaman JC, Perez-Mendez O, Hernandez-Munoz R, Torres-Duran PV, Juarez- Oropeza MA. Protective effects of Spirulina maxima on hyperlipidemia and oxidative-stress induced by lead acetate in the liver and kidney. Lipids Health Dis. 2010;9:35.

15. Shin WT, Heo JE, Kim TH, Hong SH, Kwon OS, Kim KT, et al. Clinical effect of Dodam-tang on hyperlipidemia patients. Journal of Korean Internal medicine. 2007;fal:113-8.

16. Kim BC, Lee EJ, Park CS, Park CG. The experimental study on the effects of Dansamyeum on hyperlipidemia. Journal of Korean Internal medicine. 2000;21(1):126-34.

17. Kim SC, Seo BI. Bonchojibseong. Seoul:Tree and earth. 2000:368-70.

18. Lee JT, Lee BR, Yang GY, Lee H, Yim YK. A Study on the Effect of Herbal-acupuncture with ArtemisiaecapillarisHerba at GB34 on Hyperlipidemia in Rat. Journal of Meridian&Acupoint. 2010;27(1):107-23.

19. Kim YC, Kim SM, Choi HS, Park JH, Seo BI. Preventive effects of Injinho-tang and Haninjinhotang on hyperlipidemia and liver damage induced by alcohol. J of Herbology. 2006;21(3):47-54.

20. Ham IH, Jung SW, Lee KJ, Park KH, Choi HY. Effect of the aerial part of Artemisia capillaris, and A. iwayomogi on the Hyperlipidemia of Rats induced by Triton WR-1339. J of Herbology. 2006;20(1):45-52.

21. Jung MJ. Yin Y, Heo SI, Wang MH. Antioxidant and Anticancer Activities of Extract from Artemisia capillaries. Natural Product Sciences. 2008;39(3):194-8.

22. Fernando D, Carla D, Marcelo C, Mario J, Jean-Charles F, Graciela R, et al. VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. ClinicaChemicaActa 1998;269:107-24.

23. Allan D, Katherine C. Lipid and vascular disease: what do and do not know. ClinicaChinicaActa. 1999;286:7-22.

24. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570-3.

25. AbouRjaili G, Shtaynberg N, Wetz R, Costantino T, Abela GS. Current concepts in triglyceride metabolism, pathophysiology, and treatment. Metabolism. 2010;59(8):1210-20.

26. Kwon HS, Park YM, Lee HJ, Lee JH, Choi YH, Ko SH, et al. The prevalence and clinical characteristics of the metabolic syndrome in middle-aged Korean adults. J Korean Med. 2005;68(4):359-68.

27. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part . diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Dabetic Med. 1998;15:539-53.

28. Turkoski BB. An ounce of prevention. Drugs used to treat hyperlipidemia. OrthopNurs. 2004; 23(1):58-61.

29. Becker J. Cardiovascular risk assessment and hyperlipidemia. Crit Care NursClin North Am. 2008;20(3):277-85.

30. Song YM, Kwon SU, Sung J, Ebrahim S, Smith GD, Sunwoo S, et al. Different risk factor profiles between subtypes of ischemic stroke. A case-control study in Korean men. Eur J Epidemiol. 2005;20(7):605-12.

31. Sirtori CR, Fumagalli R. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others. Atherosclerosis. 2006;186(1): 1-11.

32. Havel RJ, Rappaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:14491-9.

33. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Execute summary of the third report of the national cholesterol education p program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel ). JAMA 2001;285: 2486-97.

34. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82(4B):3J-10J.

35. Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev. 2005;23(1):15-30.

36. Kim GY, Seo IB. Study on the Curative Effects of the Semyung-Gangji-tang on the Atherosclerosis in Hyperlipidemic Rabbits. J. Korean Oriental Med. 2001;22(3):105-18.

37. Johnston TP. Poloxamer-407 as a general lipase inhibitor: its implications in lipid metabolism and atheroma formation in C57BL/6 mice. J Pharm Pharmacol. 2010;62(12):1807-12.

38. Pfizer 2008 Annual Report. Pfizer. 2008. Available at : URL:http://media. pfizer.com/files/annualreport/2008/annual/review 2008.pdf. Accessed June 10, 2010.

39. Lee JM, Chae KS, Ha JR, Park BY, Lee HS, Jeong SH, et al. Regulation of obesity and lipid disorders by herbal extracts from Morus alba, Melissa officinalis, and Artemisia capillaris in high-fat diet-induced obese mice. J Ethnopharmacol. 2008;115(2):263-70.

40. Pan J, Liu G, Liu H, Qiu Z, Chen L. Effects of Artemisia capillaris on blood glucose and lipid in mice. Zhong Yao Cai. 1998 Aug;21(8):408-11.

41. Sekiya M, Hiraishi A, Touyama M, Sakamoto K. Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells. Biochem Biophys Res Commun. 2008;375(4):602-7.

42. Kurata M, Suzuki M, Agar NS. Antioxidant systems and erythrocyte life-span in mammals. Comp BiochemPhysiol B .1993;106(3):477-87.

43. Parke DV, Parke AL. Chemical-induced inflammation and inflammatory diseases. Int J Occup Med Environ Health 1996;9(3):211-7.

44. Magder S. Reactive oxygen species: toxic molecules or spark of life? Crit Care 2006;10(1): 208.

45. van Deel ED, Lu Z, Xu X, Zhu G, Hu X, Oury TD, et al. Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free RadicBiol Med. 2008;44(7): 1305-13.

46. Oka Y, Miyazaki M, Takatsu S, Kunitomo K, Kokumai Y, Matsuda H, et al. Lowering of oxidative stress in hemodialysis patients by dialysate cleaning: in relation to arteriosclerosis. TherApher Dial. 2004;8(4):313-9.